Ardelyx, Inc. ARDX
Regular-session close
After hours · Nov 20, 7:25 PM ET
- YTD
- -48.71%
- 1 year
- -46.13%
5D -0.11 (-3.55%)
- Market cap
- 751.60M
- Revenue (ttm)
- 450.89M
- Profit margin
- -12.35%
- EPS (ttm)
- -0.23
- Shares out
- 258.19M
- Forward P/E
- 15.44
- YTD return
- -48.71%
- 1-year return
- -46.13%
- 50-day average
- 5.09
- Volume
- 6.20M
- Avg volume
- 4.41M
- Open
- 3.01
- Previous close
- 3.06
- Day's range
- 2.95 – 3.08
- 52-week range
- 2.80 – 8.40
- Beta
- 0.73
- Analysts
- Strong Buy
- Price target
- 12.90 (+331.4%)
Key statistics
- 200-day average
- 5.97
- Enterprise value
- 972.51M
- Price / sales
- 2.23
- Price / book
- 6.51
- Revenue growth
- 23.80%
- Free cash flow
- 20.47M
- Total cash
- 281.83M
- Total debt
- 282.51M
- Return on equity
- -38.61%
- Short % of float
- 10.76%
Fundamental scorecard
9 of 25 checks passed on ARDX’s reported financials
9of 25 checks passed
- Value 2 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 30, 2026 | -0.03 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.06545 | -0.07 | 0.00 | -6.95% |
| Apr 30, 2026 | Mar 31, 2026 | -0.13 | -0.15 | -0.02 | -15.38% |
| Feb 19, 2026 | Dec 31, 2025 | 0.02 | 0.02 | 0.00 | 0.00% |
| Oct 30, 2025 | Sep 30, 2025 | -0.06 | -0.00401 | +0.06 | +93.32% |
| Aug 4, 2025 | Jun 30, 2025 | -0.13 | -0.08 | +0.05 | +38.46% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 19, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 18, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 17, 2026 | Piper Sandler | main | Overweight | Overweight |
| Aug 10, 2026 | Citigroup | main | Buy | Buy |
| Aug 7, 2026 | TD Cowen | main | Buy | Buy |
| Aug 7, 2026 | BTIG | main | Buy | Buy |
About Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ardelyx.com
News
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX
ARDX DEADLINE TODAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important November 16 Deadline in Securities Class Action - ARDX
ARDELYX (NASDAQ: ARDX) CLASS ACTION DEADLINE TODAY: Faruqi & Faruqi, LLP Reminds Investors of November 16, 2026 Lead Plaintiff Deadline
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
ARDX DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important November 16 Deadline in Securities Class Action - ARDX
ARDX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
ARDX DEADLINE: ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important November 16 Deadline in Securities Class Action - ARDX
Your note
Sign in to keep a note on ARDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERTRAND WILLIAM C JR | Director | Stock Award(Grant) | Jun 15, 2026 | 329,507 |
| BISHOP JOHN E | Officer | Sale | May 20, 2026 | 336,845 |
| FOSTER ERIC DUANE | Officer | Sale | May 20, 2026 | 417,972 |
| KELLIHER MICHAEL | Officer | Sale | May 20, 2026 | 357,418 |
| MOTT DAVID M | Director | Stock Award(Grant) | Jun 15, 2026 | 3,349,660 |
| RAAB MICHAEL G | Chief Executive Officer | Sale | Jul 14, 2026 | 1,703,730 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.43% | 23,504,630 | 91.43M | Jun 29, 2026 |
| Rubric Capital Management LP | 6.50% | 16,202,700 | 63.03M | Jun 29, 2026 |
| Millennium Management Llc | 5.58% | 13,900,773 | 54.07M | Jun 29, 2026 |
| State Street Corporation | 5.36% | 13,356,128 | 51.96M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.20% | 10,471,494 | 40.73M | Jun 29, 2026 |
| Nomura Asset Management International Inc | 3.83% | 9,546,732 | 37.14M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.97% | 7,404,867 | 28.80M | Mar 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.97% | 7,389,361 | 28.74M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.57% | 6,400,256 | 24.90M | Jun 29, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.51% | 6,265,909 | 24.37M | May 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.08% | 2,702,696 | 10.51M | Mar 30, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.96% | 2,392,375 | 9.31M | May 30, 2026 |
